1453861-66-9

Basic information

• Product Name: ethyl 2-(3-(4-((2'-chloro-4'-((tetrahydro-2H-pyran-4-yl)methoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetate
• Synonyms: ethyl 2-(3-(4-((2'-chloro-4'-((tetrahydro-2H-pyran-4-yl)methoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetate
• CAS NO: 1453861-66-9
• Molecular Weight: 551.079
• Mol File: 1453861-66-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: ethyl 2-(3-(4-((2'-chloro-4'-((tetrahydro-2H-pyran-4-yl)methoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(3-(4-((2'-chloro-4'-((tetrahydro-2H-pyran-4-yl)methoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetate(1453861-66-9)
• EPA Substance Registry System: ethyl 2-(3-(4-((2'-chloro-4'-((tetrahydro-2H-pyran-4-yl)methoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetate(1453861-66-9)

Safety Data

• Hazardous Substances Data: 1453861-66-9(Hazardous Substances Data)

Upstream product

• 1449228-41-4 ethyl 2-(3-(4-hydroxyphenyl)oxetan-3-yl)acetate 
• 1453861-34-1 ethyl 2-(3-(4-((4'-hydroxy-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetate 
• 922500-91-2 ethyl 2-(oxetan-3-ylidene)acetate 
• 14774-37-9 (tetrahydro-2H-pyran-4-yl)methanol 
• 1453861-55-6 ethyl 2-(3-(4-((2'-chloro-4'-hydroxy-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetate 
• 101691-65-0 toluene-4-sulfonic acid tetrahydropyran-4-ylmethyl ester 
• 1453862-21-9 ethyl 2-(3-(4-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)phenyl)oxetan-3-yl)acetate 
• 1453862-20-8 ethyl 2-(3-(4-((3-bromobenzyl)oxy)phenyl)oxetan-3-yl)acetate 

Downstream Products

• 1453861-67-0 2-(3-(4-((2'-chloro-4'-((tetrahydro-2H-pyran-4-yl)methoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetic acid 

Relevant articles and documents

PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS

The present invention relates to phenyl alkanoic acid derivatives (the compounds of Formula (I)); and their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, polymorphs, N-oxides, S-oxides or carboxylic acid isosteres thereof. The invention also relates to processes for the preparation of compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds of Formula (I). The said compounds and the pharmaceutical composition function as GPR (G-protein coupled receptor) agonists, particularly as GPR40 agonists, and are useful in the treatment of diseases or conditions mediated by GPR40. The present invention further relates to a method of treatment of diseases or conditions mediated by GPR40comprising administering to a subject in need thereof a therapeutically effective amount of the compounds of Formula (I).